Bruceantin
Names | |
---|---|
IUPAC name
Methyl (1R,2S,3R,6R,8R,13S,14R,15R,16S,17S)-3-[(E)-3,4-dimethylpent-2-enoyl]oxy-10,15,16-trihydroxy-9,13-dimethyl-4,11-dioxo-5,18-dioxapentacyclo[12.5.0.01,6.02,17.08,13]nonadec-9-ene-17-carboxylate
| |
Other names
Bruceantine
| |
Identifiers | |
3D model (
JSmol ) |
|
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C28H36O11 | |
Molar mass | 548.585 g·mol−1 |
Melting point | 225–226 °C (437–439 °F; 498–499 K)[1] |
Hazards | |
Lethal dose or concentration (LD, LC): | |
LD50 (median dose)
|
mouse (male, IV) 1.95 mg/kg mouse (female, IV) 2.58 mg/kg[1] |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Bruceantin is a chemical compound that was first isolated from the plant Brucea antidysenterica in 1973.[2] Chemically, it is classified as a secotriterpenoid and a quassinoid.
Bucreantin has attracted interest as a potential antitumor drug because of its
antineoplastic activity.[3] It inhibits the peptidyl transferase elongation reaction, resulting in decreased protein and DNA synthesis.[3] Bruceantin also has antibiotic, antiamoebic,[4] and antimalarial activity.[3]
Phase I and II clinical trials were conducted for the treatment of metastatic breast cancer and malignant melanoma, but tumor regression was not observed and clinical development was terminated.[5][6]
References
- ^ a b Merck Index, 12th Edition, 1475
- PMID 4682660.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - ^ a b c "Bruceantin". NCI Cancer Dictionary. National Institutes of Health.
- PMID 6100431.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - PMID 14987068.
- ^ "Bruceantin". Inxsight Drugs.